NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Teva Pharmaceutical Industries Limited TEVA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$17.3B
▲ 4.3% vs FY2024
EPS · FY25
$1.21
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
21.2%
Net margin · FY25
8.2%
Dividend coverage
-19.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 17.3B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
8 cents of every revenue dollar became profit this year.
Per share
USD 1.21
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
21.2%
Return on equity, FY2025
ROE
Operating margin12.5%
Net margin8.2%
Return on assets3.5%
Each USD of equity produced 21 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+0.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.0%
+0.7%
+0.5%
Net income
−5.6%
EPS, diluted
−7.1%
Returned to shareholders
−61.9%
−29.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 40.7B
total assets, end of FY2025
Total assetsUSD 40.7B
EquityUSD 7.9B
CashUSD 3.6B
Gross debtUSD 1.8B
Net debtUSD -1.8B
Current ratio1.04×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2013
2012
2011
2010
2009
2008
2007
Revenue $B
17.3
16.5
15.8
14.9
15.9
16.7
16.9
18.3
21.9
21.9
20.3
20.3
18.3
16.1
16.1
11.1
9.4
Operating income $B
2.2
−0.3
0.4
−2.2
1.7
−3.6
−0.4
−1.6
−17.5
2.2
1.6
2.2
3.1
3.9
2.4
1.1
2.4
EBITDA $B
2.6
0.2
1.0
−1.6
2.2
−3.0
0.2
−1.0
−16.9
2.7
2.1
2.6
3.5
4.3
2.8
1.5
·
Income tax $B
−0.2
0.7
−0.0
−0.6
0.2
−0.2
−0.3
−0.2
−1.9
0.5
−0.0
−0.1
0.1
0.3
0.2
0.2
0.4
Net income $B
1.4
−1.6
−0.6
−2.4
0.4
−4.0
−1.0
−2.1
−16.3
0.3
1.3
2.0
2.8
3.3
2.0
0.6
1.9
EPS, diluted $
1.21
−1.45
−0.50
−2.20
0.38
−3.64
−0.91
−2.35
−16.26
0.07
1.49
2.25
3.09
3.67
2.23
0.75
2.36
Dividend / sh $
·
·
·
·
·
·
0.00
0.00
0.85
1.36
1.28
1.03
0.89
0.74
0.61
0.50
·
Payout %
·
·
·
·
·
·
·
−1
−6
396
86
44
29
20
26
64
16
ROE %
21.2
−25.5
−7.3
−27.1
4.1
−33.3
−7.0
−13.4
−93.7
·
5.6
8.7
12.5
16.2
11.2
3.7
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
0.94
0.92
0.89
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
64 of 64
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed